Scientists have made a groundbreaking discovery in understanding the BRCA2 gene, offering new hope for cancer patients and those at high risk of developing the disease.

Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...